Urologix Shakes Off Reimbursement Woes; Stock Is Up Nearly 80% In July
This article was originally published in The Gray Sheet
Executive SummaryUrologix' announcement that its Targis microwave system likely will be reimbursed on par with other minimally invasive therapies for benign prostatic hyperplasia under the Health Care Financing Administration's physician fee schedule signaled that the firm's payment problems may finally be coming to an end. The issue ended July up 78.5%.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.